This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Theragenics Reports Fourth Quarter And Year-End 2012 Results

Stocks in this article: TGX

Theragenics Corporation ® (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced consolidated financial results for the fourth quarter and year ended December 31, 2012.

Consolidated Results

  • Consolidated revenue
    • $19.1 million in the fourth quarter, down 4% from 2011
    • $82.6 million for the year, flat compared with 2011
  • Earnings per share
    • Loss of $0.01 in fourth quarter compared to earnings of $0.01 in 2011
    • Earnings of $0.07 for 2012 compared to $0.09 in 2011
  • Cash flow from operations of $13.2 million in 2012 compared to $6.1 million in 2011
  • Adjusted EBITDA
    • $2.0 million in fourth quarter compared to $2.6 million in 2011
    • $12.6 million in 2012 compared to $13.5 million in 2011
  • At December 31, 2012 cash, cash equivalents and marketable securities were $34.9 million and credit facility borrowings were $22.0 million, resulting in a net positive position of $12.9 million

Segment Results

  • Revenue
    • Surgical products
      • $14.3 million in the fourth quarter, flat compared to 2011
      • $59.9 million for the year, up 1% from 2011
    • Brachytherapy
      • $5.1 million for the quarter, down 12% from 2011
      • $23.6 million for the year, down 2% from 2011
        • Incremental revenue in the Brachytherapy segment from acquired Core customers was $793,000 in the fourth quarter and $3.6 million for the year
      • Operating income
        • Surgical products
          • Loss from operations of $334,000 in the fourth quarter compared to a loss of $480,000 in 2011
          • Operating income of $696,000 for the year compared to $607,000 in 2011
        • Brachytherapy
          • Operating income of $89,000 in fourth quarter, compared to $1.1 million in 2011
          • Operating income of $3.1 million for the year compared to $4.9 million in 2011

Comments

“The momentum from our first half of 2012 was erased in the second half of 2012,” stated M. Christine Jacobs, Chairman and CEO. “We faced sector-wide anemic growth and continuing customer uncertainty resulting in soft demand across all of our business units. Every strategic accomplishment of 2012 was masked by soft demand and the high fixed cost components of our operations.”

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,719.00 +33.27 0.19%
S&P 500 2,052.75 +4.03 0.20%
NASDAQ 4,701.8670 +26.1550 0.56%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs